UNSPSC 51401517: Cloxazolam

This classification denotes an anxiolytic with the molecular formula C17H14Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GYL649Z0HY, chemically known as 10-chloro-2,3,5,6,7,11b-hexahydro-11b-(o-chlorophenyl)benzo(6,7)-1,4-diazepino-(5,4-b)-oxazol-6-one but generally known as cloxazolam, which bears US NIH Compound Identifier 2816. European Medicines Agency schedules Cloxazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06781MIG.

UNSPSC 51401517 Cloxazolam, a Commodity code, nominally designates a single pharmaceutical agent, but the recent state and local opportunities tagged under it span a broader pharmacy procurement landscape—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. State and local health departments, human services commissions, and cooperative purchasing alliances are the primary issuing bodies, with health and safety agencies seeking both emergency-response medications and routine pharmacy supply chain management. The scope under this code in practice includes procurement of naloxone for community health programs, generic pharmaceutical sourcing through authorized wholesalers with strict compliance requirements, and exploratory contracting mechanisms to reform pharmacy benefit delivery. Issuers range from county health departments to state health and human services commissions and multistate cooperative purchasing organizations serving multiple jurisdictions.

Recent activity is concentrated in Florida and Texas, with national multistate coordination through Minnesota's cooperative purchasing vehicle. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: due date predates posting date in source), under a two-year term with one-year renewal option and fixed-fee pricing. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory procurement phase without formal evaluation criteria or award values. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in multiple states including Oregon, requiring vendors to supply through three authorized wholesalers with cGMP and Drug Supply Chain Security Act compliance, pricing weighted 75 percent of evaluation, and a two-year initial term.